On December 20, 2023, TARPEYO received full FDA approval for the new indication to reduce the loss of kidney function in adults with IgA Nephropathy (IgAN) who are at risk for their disease getting worse.
“This first-ever IgAN treatment to get a full approval based on kidney function represents a beacon of hope for the entire IgA nephropathy community and signifies a critical step forward in the battle against IgAN,” said Bonnie Schneider, director and cofounder of the IgAN Foundation. “The foundation is elated and personally this is so rewarding and validating after a near 20-year journey since founding this volunteer-run organization to raise awareness and promote research for IgAN.”
Read the full press release here
FAQS here
8 Tips for taking control of your blood pressure 